teal triangle graphic

Medical Education Grants

Medical Education Grants

Alkermes supports continuing medical education with grants for educational activities focused on pragmatic approaches to improving patient care and public health. We hope to contribute to an improved understanding of the underlying mechanisms of the diseases we research and their relevance to medications, as well as psychosocial interventions.

Grant funding may be available for activities, including live, print, enduring or web-based continuing medical education (CME) activities. Accredited CME activities are preferred.

Alkermes is currently accepting grant proposals related to:

  • Schizophrenia
  • Bipolar Disorder
  • Alcohol Use Disorder 
  • Oncology
    • Platinum-Resistant Ovarian Cancer
    • Mucosal Melanoma

      Apply now

Who May Apply

Only organizations based in the U.S. may apply. Medical education grants may be awarded to (i) nonprofit organizations with tax exempt status under the U.S. Internal Revenue Code or (ii) for-profit organizations that are accredited continuing medical education providers.

How to Apply

Requests must be submitted online by the educational provider. Submissions are due at least 90 days in advance of the activity date. 

Application portal

Areas of Interest

Alkermes is currently accepting proposals that address the topic areas listed below for Schizophrenia, Bipolar Disorder and Alcohol Use Disorder. Starting October 25th, 2022, Alkermes will accept proposals for an RFP for continuing medical education programs about Alcohol Use Disorder.


  • Understanding and implementing pharmacologic approaches to address one or more of the following challenges in the treatment of schizophrenia:
    • Suboptimal therapeutic response
    • Gaps in medication adherence
    • Side effects associated with treatment
  • Emerging pharmacologic approaches and their mechanism of action for the treatment of schizophrenia
  • Using patient-centered approaches to optimize treatment of schizophrenia

Bipolar Disorder

  • Understanding and implementing pharmacologic approaches to address one or more of the following challenges in the treatment of bipolar disorder:
    • Suboptimal therapeutic response
    • Gaps in medication adherence
    • Side effects associated with treatment
  • Emerging pharmacologic approaches and their mechanisms of action for the treatment of bipolar disorder
  • Using patient-centered approaches to optimize treatment of bipolar disorder

Alcohol Use Disorder

Areas of Interest 

  • Education around the use of standardized screening tools
  • Support for motivational interviewing 
  • Pharmacological evidence-based treatment

Nearly 28 million people in the U.S. have Alcohol Use Disorder. However, less than 10% of people who have AUD receive treatment, defined as any treatment or counselling designed to help reduce or stop alcohol use1. Recently published data showed that most patients (81.4%) with AUD both have access and have utilized healthcare within the past 12 months. Given the relatively high rate of healthcare utilization that already exists for AUD patients, there is great opportunity to significantly improve AUD treatment through expansion of adequate screening, brief intervention (including motivational interviewing), treatment referral, and pharmacotherapy in frontline healthcare provider settings where patients are already receiving other healthcare2.

Request for Proposals - Alcohol Use Disorder (RFP#: 2022-RFP-AUD-01)

Application Requirements: 

Proposals must be submitted to the Alkermes Grant Management System between October 25 and November 30, 2022. Any proposal submitted outside of this period will not be eligible for RFP consideration.

Proposals must reference RFP#: 2022-RFP-AUD-01 in the program title.

Recipients will be selected by the Alkermes Grants Review Committee and notified in December 2022.

The following additional guidelines apply:

  • Programs with patient-centric content, interactive elements, a focus on practical learning and clinical case studies will be prioritized.   
  • Programs that provide robust medical education outcomes plans will be prioritized. Ideal proposals will have specific plans for measuring program impact, including an assessment of the educational gains made and identification of any persistent educational gaps, with sub-analyses by learner type.
  • Priority will be given to programs that develop enduring materials and that identify best practices based on the consensus view of experts in the fields of alcohol use disorder research and clinical practice.
  • The target audiences for learners are frontline healthcare providers and medication prescribers, including but not limited to emergency medicine physicians, PCP physicians, PAs, APNs, and nurses.
  • Educational activities must be accredited (CME/CE), and collaborations between medical education companies, medical societies and academic institutions are strongly encouraged.
  • Programs must be able to launch within 60 days of award date.

Click here to apply


1. National Institute on Alcohol Abuse and Alcoholism. Alcohol facts and statistics. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts-and-statistics. Accessed July 25, 2021. 

2. Mintz CM, Hartz SM, Fisher SL, Ramsey AT, Geng EH, Grucza RA, Bierut LJ. A cascade of care for alcohol use disorder: Using 2015-2019 National Survey on Drug Use and Health data to identify gaps in past 12-month care. Alcohol Clin Exp Res. 2021 Jun;45(6):1276-1286.

teal triangle graphic

Additional Information

Alkermes is committed to complying with all applicable regulations and codes pertaining to education grants. Alkermes follows the requirements of the Compliance Program Guidance for Pharmaceutical Manufacturers issued by the Department of Health and Human Services Office of the Inspector General (“OIG Guidelines”), the Pharmaceutical Research and Manufacturers of America Code on Interactions with Healthcare Professionals (“PhRMA Code”), the FDA Guidance to Industry Supported Scientific and Educational Activities and the Accreditation Council for Continuing Medical Education (“ACCME”) Standards for Commercial Support. Alkermes does not provide support for education programs that are intended to encourage, induce or influence any grant recipient to purchase, prescribe, refer, recommend, sell, administer or arrange for the purchase, sale or recommendation or formulary placement of any Alkermes product.
For more information, please contact: Med.Ed@alkermes.com.